[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19]. / Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19.
Reumatol Clin
; 17(6): 309-312, 2021.
Article
en Es
| MEDLINE
| ID: mdl-38620280
ABSTRACT
The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ß. We propose its use in controlling ARDS secondary to COVID-19 infection.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
Es
Revista:
Reumatol Clin
Año:
2021
Tipo del documento:
Article
Pais de publicación:
España